- Home
- MLYS vs GHRS Comparison
MLYS vs GHRS Comparison
Compare MLYS & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- GHRS
- Stock Information
- Founded
- MLYS 2019
- GHRS 2018
- Country
- MLYS United States
- GHRS Ireland
- Employees
- MLYS N/A
- GHRS N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- MLYS Health Care
- GHRS Health Care
- Exchange
- MLYS Nasdaq
- GHRS Nasdaq
- Market Cap
- MLYS 890.6M
- GHRS 874.0M
- IPO Year
- MLYS 2023
- GHRS 2021
- Fundamental
- Price
- MLYS $37.16
- GHRS $12.46
- Analyst Decision
- MLYS Strong Buy
- GHRS Strong Buy
- Analyst Count
- MLYS 6
- GHRS 8
- Target Price
- MLYS $42.60
- GHRS $30.63
- AVG Volume (30 Days)
- MLYS 2.6M
- GHRS 183.0K
- Earning Date
- MLYS 11-10-2025
- GHRS 08-07-2025
- Dividend Yield
- MLYS N/A
- GHRS N/A
- EPS Growth
- MLYS N/A
- GHRS N/A
- EPS
- MLYS N/A
- GHRS N/A
- Revenue
- MLYS N/A
- GHRS N/A
- Revenue This Year
- MLYS N/A
- GHRS N/A
- Revenue Next Year
- MLYS N/A
- GHRS N/A
- P/E Ratio
- MLYS N/A
- GHRS N/A
- Revenue Growth
- MLYS N/A
- GHRS N/A
- 52 Week Low
- MLYS $8.24
- GHRS $6.00
- 52 Week High
- MLYS $39.20
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- MLYS 86.84
- GHRS 38.54
- Support Level
- MLYS $35.00
- GHRS $13.71
- Resistance Level
- MLYS $15.79
- GHRS $14.59
- Average True Range (ATR)
- MLYS 2.50
- GHRS 0.75
- MACD
- MLYS 2.05
- GHRS -0.04
- Stochastic Oscillator
- MLYS 91.73
- GHRS 2.07
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.